KDR and microtia: However, our data demonstrated that therapeutic inhibition of VEGFR-1 and VEGFR-2 with sunitinib, a small molecule broad-spectrum receptor tyrosine kinase inhibitor, resulted in more pathology in experimental MA-ARDS, whereas specific inhibition of VEGFR-2 had no effect (Supplementary Figure 4).